Pharmacopeia, Inc. (NDAQ: PCOP) shares continued their decline today after the company received a delisting notice from the Nasdaq Stock Market. The company actually received the notice on September 30th indicating that it was not in compliance with the continued listing requirements because the market value of its listed securities was below $50 million for 10 consecutive trading days. This could spell bad news for shareholders as liquidity is greatly reduced upon delisting.

The company is currently involved in a deal to be acquired by Ligand Pharmaceuticals Incorporated (NDAQ: LGND) in a deal valued up to $70 million. The deal is based off of the price of Ligand shares, which have fallen sharply in recent days. The transaction is structured as a stock-for-stock exchange with an added kicker. Ligand willissue about 17.5 million shares, or 0.58 shares for each outstanding Pharmacopeia share. This will give Ligand 84% of the combined company.

Pharmacopeia is a clinical development stage biopharamceutical company dedicated to discovering and developing small molecule therapeutics to address medical needs. It has a portfolio of clinical and preclinical candidates under development internally or by partners, including eight clinical compounds in Phase II or Phase I development addressing multiple indications, including hypertension, diabetic nephropathy, muscle wasting, inflammation and respiratory disease.

Related Companies
Wyeth (WTE)
Cephalon, Inc. (CEPH)
Allergan Inc. (AGN)
Celgene Corporation (CELG)

Warren Buffett is well-recognized as a smart investor, which should be giving investors a clue. The billionaire investor has recently agreed to purchase shares in two institutions facing sharp declines: General Electric (NYSE: GE) and Goldman Sachs (NYSE: GS). Many investors are speculating that he was brought into these deals to calm fears, but he is not exactly playing on a level field. Under both of these deals, the billionaire receieved preferential treatment...

The billionaire purchased a $5 billion stake in Goldman Sachs last month, but it wasn't just common stock. The billionaire received $5 billion in perpetual preferred stock and 43.5 million warrants priced at $115 per share. These warrants give the investor a theoretical 16% stake in Goldman Sachs - one of the world's premier investment banks - for only $5 billion in investment. In fact, with shares trading at around $130 a piece, Buffett has already made $650 million in paper profits!

Buffett also managed to pick up cheaper than normal shares of General Electric. The billionaire invested $3 billion at a 9% discount to the stock's closing price Wednesday to buy up preferred stock that pays a 10% dividend. Buffett also stated that he would support measures to alleviate near-term liquidity concerns. Not only is the billionaire making a dividend on his investment, but he is also receiving a sharp discount.

So, before investors go believing that Warren Buffett's investments signal confidence - they should be sure to take a look at the terms of the deals...

Related Companies
Deutsche Bank AG (DB)
Credit Suisse Group (CS)
Friedman, Billings, Ramsey Group (FBR)

thinkorswim Group Inc. (NDAQ: SWIM) shares jumped higher after the company reported preliminary operating metrics for September 2008 early due to extraordinary price volatility, regulatory intervention and liquidity concerns. During this time period, thinkorswim delivered its 24th consecutive month of record growth by opening 8,550 new accounts, 3,400 funded accounts, executive 63,600 retail DARTs and maintaining client assets of approximately $3.2 billion.

Trading volumes at thinkorswim exceeded 96,000 retail trades in a single day during the month and now expects to outperform analyst consensus for the third quarter. Many brokerages have benefited from from the increased market activity as they have collected more in commissions. However, some brokerages have failed to offset these gains with losses from margin accounts that have defaulted.

thinkorswim Group Inc., formerly Investools Inc. (Investools) operates in two segments: Investor Education and Brokerage Services. The Company offers investor education and brokerage and related financial products and services for self-directed investors. Its Investor Education segment offers a range of investor education products and services that provide learning in a variety of interactive delivery formats.

Related Companies
Capella Education Company (CPLA)
Apollo Group, Inc. (APOL)
Strayer Education, Inc. (STRA)